| Drug Name |
Memantine |
| Drug ID |
BADD_D01378 |
| Description |
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease [A1639]. Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease [T556].
In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 [F4366]. In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 [L5953, F4366]. |
| Indications and Usage |
For the treatment of moderate to severe dementia of the Alzheimer's type. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N06DX01 |
| DrugBank ID |
DB01043
|
| KEGG ID |
D08174
|
| MeSH ID |
D008559
|
| PubChem ID |
4054
|
| TTD Drug ID |
D01JEU
|
| NDC Product Code |
0615-8192; 0904-6505; 53746-173; 60687-173; 0615-8319; 65162-173; 60687-184; 65015-892; 53746-169; 0904-6506; 24196-184; 65162-169; 70518-3297; 55111-596; 55154-7637; 55111-597 |
| Synonyms |
Memantine | Memantin | 1,3-Dimethyl-5-aminoadamantane | 1-Amino-3,5-dimethyladamantane | Namenda | Ebixa | Memantine Hydrochloride | Axura | D-145 | D 145 | D145 |
